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ABSTRACT 
BACKGROUND & AIMS: Parenteral methotrexate is an effective treatment for patients with Crohn's disease, 
but has never been adequately evaluated in patients with ulcerative colitis (UC). We conducted a randomized 
controlled trial to determine its safety and efficacy in patients with steroid-dependent UC.  
METHODS: We performed a double-blind, placebo-controlled trial to evaluate the efficacy of parenteral 
methotrexate (25 mg/wk) in 111 patients with corticosteroid-dependent UC at 26 medical centers in Europe from 
2007 through 2013. Patients were given prednisone (10 to 40 mg/d) when the study began and were randomly 
assigned to groups (1:1) given placebo or methotrexate (intramuscularly or subcutaneously, 25 mg weekly) for 
24 weeks. The primary end point was steroid-free remission (defined as a Mayo score ≤2 with no item >1 and 
complete withdrawal of steroids) at week 16. Secondary endpoints included clinical remission (defined as a 
Mayo clinical subscore ≤2 with no item >1) and endoscopic healing without steroids at weeks 16 and/or 24, 
remission without steroids at week 24, and remission at both weeks 16 and 24. 
RESULTS: Steroid-free remission at week 16 was achieved by 19 of 60 patients given methotrexate (31.7%) 
and 10 of 51 patients given placebo (19.6%)—a difference of 12.1% (95% confidence interval [CI]: -4.0% to 
28.1%; P = .15). The proportion of patients in steroid-free clinical remission at week 16 was 41.7% in the 
methotrexate group and 23.5% in the placebo group, for a difference of 18.1% (95% CI: 1.1% to 35.2%; P = 
.04). The proportions of patients with steroid-free endoscopic healing at week 16 were 35% in the methotrexate 
group and 25.5% in the placebo group—a difference of 9.5% (95% CI: -7.5% to 26.5%; P = .28). No differences 
were observed in other secondary end points. More patients receiving placebo discontinued the study because of 
adverse events (47.1%), mostly caused by UC, than patients receiving methotrexate (26.7%; P = .03). A higher 
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proportion of patients in the methotrexate group had nausea and vomiting (21.7%) than in the placebo group 
(3.9%; P = .006).  
CONCLUSIONS: In a randomized controlled trial, parenteral methotrexate was not superior to placebo for 
induction of steroid-free remission in patients with UC. However, methotrexate induced clinical remission 
without steroids in a significantly larger percentage of patients, resulting in fewer withdrawals from therapy due 
to active UC. ClinicalTrials.gov ID NCT00498589.  
Keywords: IBD; Methotrexate; Clinical Trial; Drug. 
Abbreviations used in this paper: CD, Crohn's disease; CI, confidence interval; GETAID, Groupe d'Étude 
Thérapeutique des Affections Inflammatoires Digestives; TNF, tumor necrosis factor; UC, ulcerative colitis. 
 
Ulcerative colitis (UC) is an inflammatory bowel disease characterized by chronic mucosal inflammation, bloody 
diarrhea, and abdominal pain. UC has a global prevalence of about 8 million, and the incidence and prevalence 
are increasing worldwide. Current medical therapies have limitations. Aminosalicylates are only effective in 
mild-to-moderate disease. Glucocorticoids cause unacceptable adverse events and do not provide a benefit as 
maintenance therapy. Azathioprine is effective for maintenance of remission,1 but is associated with an increased 
risk of infection2 and lymphoma.3 Although tumor necrosis factor (TNF) antagonists (anti-TNFs) are 
efficacious,4,5 they are not effective in all patients; their use is limited by low long-term remission rates and by a 
risk of severe infections, including opportunistic infections.6 Anti-adhesion molecules, which reduce 
inflammation by preventing lymphocytes trafficking to the gut mucosa, constitute a novel drug class in this 
indication7, however, their precise role in treatment algorithms is not yet fully defined. The introduction of new 
biologic therapies has a strong impact on health care expenditures. In the current era of escalating health care 
costs and growing constraints on health care budgets,8 need exists for alternative, safe, and inexpensive drugs in 
UC. 
Methotrexate is a dihydrofolate reductase that has been used for decades for treatment of psoriasis and 
rheumatoid arthritis. In Crohn's disease (CD), methotrexate has proven efficacy as induction and maintenance 
therapy, at a dosage of 25 mg weekly intramuscularly.9,10 A Cochrane review concludes that there is insufficient 
evidence to support the use of methotrexate for induction or maintenance of remission in UC, although the only 
included controlled trial used an oral dosage of 12.5 mg/wk.11,12 We therefore conducted a multicenter, 




This METEOR (Controlled, Randomized, Double-Blind, Multicentre Study Comparing Methotrexate vs Placebo 
in Steroid Dependant Ulcerative Colitis) trial was conducted at 26 medical centers in 6 countries (Austria, 
Belgium, Finland, France, Greece, and Italy) from 2007 to 2013. French and Belgian centers were affiliated with 
the Groupe d'Étude Thérapeutiques des Affections Inflammatoires Digestives (GETAID). The trial was designed 
by investigators of the GETAID and European Crohn's and Colitis Organisation. Written informed consent was 
obtained from all participants. The study was approved by the Institutional Review Board of the University 
Hospital of Besançon (France), by the French Health Authority (Agence Française de Sécurité Sanitaire des 
Produits de Santé) and was registered under ClinicalTrials.gov ID NCT00498589. 
Patients 
Eligible patients were adults younger than 75 years of age who had been diagnosed with UC for at least 6 
months and were steroid-dependent, as defined by at least one unsuccessful attempt to discontinue steroids 
during the last 12 weeks before inclusion. Steroid therapy may have completely stopped if it had been restarted 
within the last 90 days.13 At inclusion, the daily dose of steroids had to range between 10 and 40 mg prednisone 
or equivalent. Patients could have active or inactive disease at inclusion, as defined by a Mayo Clinic score 
(range, 0—12, with higher scores indicating more active disease) of >2 or ≤2. At the beginning of the trial, 
patients included had to have inactive disease, but in November 2009, due to slow recruitment, an amendment 
allowed inclusion of patients with active or inactive disease. Patients with a child-bearing potential were required 
to use an adequate method of contraception throughout the study. Patients were ineligible if they were initially 
refractory to oral steroids (no improvement after 2 weeks of 40 mg prednisone), had received anti-TNFs within 
60 days before enrollment, or had received azathioprine, mercaptopurine, cyclosporine, nonsteroidal anti-
inflammatory drugs, cotrimoxazole, or probenecid within 30 days before enrollment. Other exclusion criteria 
included indication for colectomy, alcohol consumption, chronic obstructive pulmonary disease, renal failure, 
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liver disease, pregnancy or lactation, patients without efficacious contraception, patients infected with human 
immunodeficiency virus, hepatitis B virus, hepatitis C virus, a history of a malignant condition, obesity (defined 
by body mass index >30 kg/m2), or diabetes mellitus. 
Screening and Baseline Procedures 
Assessments performed during the screening visit, 4 to 12 days before inclusion, included clinical examination, 
complete blood count, serum folates, C-reactive protein serum concentration, serum transaminases, creatinine 
and albumin serum concentration, serum pregnancy test for women of childbearing potential, hepatitis B virus, 
hepatitis C virus, and human immunodeficiency virus antibodies, chest x-rays, and sigmoidoscopy. Total Mayo 
score was determined immediately before randomization. At the same time, an inflammatory bowel disease 
quality of life questionnaire (Inflammatory Bowel Disease Questionnaire; range, 0—224, with higher scores 
indicating a better quality of life) was administered. 
Randomization Procedures 
Randomization was centralized and balanced by center. The 1:1 randomization sequence was generated 
independently of the investigators by the Clinical Investigation Center of Lille University Hospital, using a 
computer procedure, with a block size of 4. The placebo and the active treatment were numbered according to 
the randomization code and then distributed by Eurofins (Nantes, France). Patients received placebo or 
methotrexate (intramuscularly or subcutaneously, 25 mg weekly), for 24 weeks. Patients, caregivers, 
investigators, and data analysis personnel were unaware of the treatment assignment. An independent blinded 
observer supervised the study and recorded any adverse effects of treatment. 
Study Medications 
Methotrexate, supplied by Sanofi-Aventis France, was packaged in 25-mg vials. Placebo, identical in appearance 
to active drug, was manufactured by EVOTEC (Glasgow, Scotland). Methotrexate and placebo were 
administered intramuscularly or subcutaneously, which is similar as far as pharmacokinetics.14,15 The injections 
were performed at patients' homes by nurses who were blinded to the study medication. A 5-mg tablet of folic 
acid was prescribed every week, 24 to 48 hours after the methotrexate or placebo injection. Ondansetron was 
allowed in the protocol, but the use of antiemetics was not recorded. The prednisone/prednisolone dosage at 
inclusion was kept unchanged during the first weeks after inclusion, according to a pre-established scheme in 
which the duration of maintenance of starting dosage of steroids was inversely correlated with this dosage 
(Supplementary Table 1). The steroid dosage was tapered by 5 mg every week, up to the dosage of 10 mg/d and 
then tapered by 2.5 mg every week until discontinuation. Therefore, all patients were scheduled to stop steroids 
at week 13, irrespective of their starting dosage. In the case of relapse after full weaning, steroids were restarted 
at a dosage of 20 mg/d and maintained during 1 week after clinical remission (defined by a partial Mayo score 
≤2, with no item >1 for the clinical part of the score). Then, the tapering schedule, as described, was resumed. If 
the patient failed to respond to a dosage of 20 mg prednisone per day, systemic steroid therapy was increased at 
the investigator's discretion. Most patients who restarted or increased steroids during the tapering process could 
not be off steroids at week 13 because of the prespecified tapering regimen. But all patients had to be off steroids 
at week 16 to meet the primary end point. 
Cotrimoxazole, salicylates, steroid-based enemas, or suppositories were prohibited. Initiation of azathioprine/ 6-
mercaptopurine, cyclosporine, tacrolimus, infliximab, or adalimumab therapy was considered failure of 
treatment and led to study discontinuation. 
Follow-up 
At each center, 2 physicians, who were unaware of the treatment assignment, followed the patients. One carried 
out the clinical follow-up and performed the endoscopies, while the other one reviewed laboratory results and 
adjusted study drug dosages based on serum transaminases complete blood counts and serum creatinine. The 
physician who ensured the clinical follow-up was unaware of laboratory results and dosage adjustments. The 
physician who reviewed biologic results was not involved in patient evaluations. 
Patients were evaluated at weeks 2, 4, and then every 4 weeks until week 24. At each visit, a partial Mayo score 
(ie, the Mayo score without the endoscopic subscore) was assessed and adverse events were recorded. Steroid 
dosages were recorded and adapted according to the pre-established tapering scheme. Blood samples for 
biochemical and hematologic testing were obtained at each visit. Flexible sigmoidoscopies were performed at 
baseline and at weeks 16 and 24 by a local investigator who was unaware of the treatment allocation and scored 
according to the Mayo endoscopic subscore. No central endoscopy reading was used. Inflammatory Bowel 
Disease Questionnaire scores were repeated at weeks 16 and 24. 
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Outcomes 
The primary end point was steroid-free remission at week 16, defined as remission with a Mayo score ≤2 with no 
item >1 and complete withdrawal of steroids and no use of another immunosuppressives (IS) or anti-TNF 
therapy or colectomy. Secondary end points were steroid-free remission at week 24, remission at week 16 and 
24, endoscopic healing (Mayo endoscopic subscore = 0 or 1), clinical remission (defined as Mayo clinical 
subscore ≤2 with no item >1), all without steroids, IS, anti-TNF, or colectomy at week 16 and/or 24 as well as 
adverse events, either severe or not. Additionally, the proportion of patients with CRP concentration <5 mg/L 
and Inflammatory Bowel Disease Questionnaire score ≥170 without steroids at week 16 were determined. At the 
beginning of the trial, the primary end point was sustained remission without steroids at weeks 16 and 24. In 
June 2014, an amendment allowed changing the primary end point to remission without steroids at week 16. The 
reason was that none of the many UC trials that had been published since the design of the trial included 
sustained remission as the primary end point. The amendment was allowed while results were still blinded. 
Study Oversight 
The study was designed and implemented by GETAID. Data were managed by the Département de 
Biostatistique et Information Médicale (Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris) and 
analyzed by the statistical department of Lille University Hospital. Funding was provided by the French Ministry 
of Health (clinical research hospital program), a private gift from an anonymous patient, the Association 
François Aupetit, and the Société Nationale Française de Gastroentérologie. 
The first draft of the manuscript was written by the first author. All of the authors had access to the data and 
vouch for the validity of the data and analyses and the fidelity of the study to the protocol. All the authors made 
the decision to submit the manuscript for publication. 
Statistical Analysis 
Baseline characteristics of patients were assessed using descriptive statistics. For the analysis of the primary end 
point, steroid-free remission rates at week 16 were compared between the methotrexate and placebo groups by χ2 
test. Secondary end points were compared between groups with the same methodology. Exploratory subgroup 
analyses were performed in order to investigate the treatment effect within subgroups defined from different 
characteristics at baseline. This was done by using the χ2 test or Fisher's exact test. In addition, a logistic 
regression with an interaction between treatment and subgroup was used to test the homogeneity of relative risks 
across the subgroups. Subgroups defined by continuous variables were dichotomized according to the median 
value. Adverse events, severe adverse events, and study discontinuations were described by frequency and 
percentage and were compared between groups by χ2 tests or Fisher's exact test. 
All analyses were performed on a full intent-to-treat basis; patients withdrawn before week 16 were considered 
as failures. 
Data were analyzed with SAS software, version 9.3 (SAS, Chicago, IL). Statistical significance was considered 
if P ≤ .05. 
Sample Size 
We expected a steroid-free remission rate of 45% with methotrexate and 20% with placebo. We hypothesized 
that the effect of parenteral methotrexate in steroid-dependent UC was in the same order of magnitude as rates of 
remission observed in open trials with methotrexate in UC16; rate of steroid-free remission observed with 
azathioprine in steroid-dependent UC17; and rate of steroid-free remission observed in CD with parenteral 
methotrexate.9 Considering a 2-sided test, a type I error rate of 5%, a statistical power of 80% and an allocation 









Published in: Gastroenterology (2016), vol. 150 pp. 380-388 http://dx.doi.org/10.1053/j.gastro.2015.10.050 
Status: Postprint (Author’s version) 
 
 
Table 1.Baseline Characteristics of Patients Included in the METEOR (Controlled, Randomized, Double-Blind, 
Multicenter Study Comparing Methotrexate vs Placebo in Steroid-Dependent Ulcerative Colitis) Trial 
Characteristics All (n = 111) Placebo (n = 51) Methotrexate (n = 60) 
Age, y 42 (32-54) 42 (31 -59) 42 (33-54) 
Sex 59 (53.2) 25 (49.0) 34 (56.7) 
Body weight, k 68 (61-78) 65 (56-80) 69 (63-75) 
Current smoker 7 (6.4) 2 (4.0) 5 (8.0) 
Duration of disease, y 4 (1-10) 5 (1-10) 4 (1-10) 
Mayo total score 4.0 (2.0-6.0) 4.0 (2.0-6.0) 4.0 (2.0-6.0) 
Partial Mayo score 2 (1-4) 3.0 (1.0-4.0) 2.0 (1.0-4.0) 
Endoscopy subscore 1 (1-2) 1 (1-2) 1 (1-2) 
IBDQ score 158 (130-195) 157 (132-181) 159 (128-193) 
Site of disease    
   Distal 28 (25.2) 11 (21.6) 17 (28.3) 
   Left colon 29 (26.1) 12 (23.5) 17 (28.3) 
   Extensive 54 (48.6) 28 (54.9) 26 (43.4) 
Prednisone-equivalent dosage, mg/d 25 (15-30) 30 (20-30) 25 (11 -30) 
UC drugs received before enrollment 
   At least one UC drug 109 (98.2) 50 (98.0) 59 (98.3) 
   Mesalamine 99 (89.2) 45 (88.2) 54 (90.0) 
   Thiopurines 65 (58.6) 30 (58.8) 35 (58.3) 
   Anti-TNF 25 (22.5) 11 (21.6) 14 (23.3) 
   Cyclosporine 7 (6.3) 4 (7.8) 3 (5.0) 
Hemoglobin concentration, g/dL 13.5 (12.1-14.5) 13.7 (12.0-14.3) 13.5 (12.1-15.1) 
Abnormal hemoglobin 21 (18.9) 9 (17.7) 12 (20.0) 
CRP serum level, mg/L 4.2 (1.6-9.5) 3.7 (2.0-8.7) 4.2 (1.1-11.0) 
Abnormal CRP, >5 mg/L 38 (35.5) 17 (34.0) 21 (36.8) 
NOTE. Quantitative variables are expressed as median (range, quartile 1 -quartile 3) and qualitative variables are n (%). CRP, C-reactive 
protein; IBDQ, Inflammatory Bowel Disease Questionnaire. 
 
Results 
Baseline Characteristics and Patient Disposition 
Between October 2007 and January 2013, one hundred and twenty patients were evaluated for eligibility; 111 
were randomized and included in the analysis. Fifty-one patients were randomized in the placebo arm and 60 
were randomized in the methotrexate arm. Patient characteristics are displayed on Table 1. Twenty-six of 51 
(51.0%) patients and 20 of 60 (33.3%) patients discontinued the study in the placebo and methotrexate arms, 
respectively including 13 of 51 (25.5%) and 8 of 60 (13.3%) before week 16, respectively. Reasons for study 
discontinuation are shown in Supplementary Figure 1. 
No patient underwent colectomy during the trial. 
Primary and Secondary Outcomes 
Steroid-free remission at week 16 was present in 19 of 60 patients assigned to methotrexate (31.7%) and 10 of 
51 (19.6%) patients who received placebo (absolute risk difference = 12.1%; 95% confidence interval [CI]: -
4.0% to 28.1%; relative risk = 1.62; 95% CI: 0.83 to 3.15; P = .15). Clinical remission without steroids at week 
16 was obtained in 25 of 60 patients assigned to methotrexate (41.7%) and 12 of 51 (23.5%) patients who 
received placebo (absolute risk difference = 18.1% [95% CI: 1.1%-35.2%]; 1.77 [95% CI: 0.99—3.16]; P = .04). 
Endoscopic healing without steroids at week 16 was obtained in 21 of 60 (35.0%) patients randomized tothe 
methotrexate arm and 13 of 51 (25.5%) patients randomized to the placebo arm (difference 9.5% [95% CI: -7.5% 
to 26.5%]; 1.37 [95% CI: 0.77 to 2.46]; P = .28). The other secondary end points were not significant (Figure 1 
and Table 2). 
Post-Hoc Analyses 
Sixty-five percent of the patients who had reached endoscopic healing without steroids at week 16 were in 
remission without steroids at week 24. By comparison, 21% of the patients who had not reached endoscopic 
healing without steroids at week 16 were in remission without steroids at week 24 (relative risk = 3.11; 95% CI: 
1.89-5.14; P < .0001). 
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We compared the individual items of the Mayo clinical subscore between the 2 arms of the study (Table 3). 
Patients assigned to methotrexate were more likely to have complete absence of rectal bleeding or diarrhea and 
no steroids at week 16 than those assigned to placebo. 
In subgroup analyses, the largest treatment effect was observed in patients with a dosage of corticosteroids <20 
mg/d at baseline (success rate 37.9% for the methotrexate arm compared with 13.6% in those assigned to 
control; Supplementary Table 3). Nevertheless, the interaction test was not significant (P =.18). 
We sought an additional indicator of efficacy by measuring the proportions of patients in each group who 
continued to experience UC activity as an adverse event. There were significantly more patients with continuing 
UC activity within the placebo arm than in the methotrexate arm (24 of 51 [47.1%] vs 13 of 60 [21.7%], 
respectively; P = .005). In addition, more patients who received placebo discontinued treatment due to persistent 
disease activity than patients who received methotrexate (21 of 51 [41.2%] vs 11 of 60 [18.3%], respectively; P 
< .008). 
Safety 
Adverse events are displayed in Table 4. Ten patients had severe adverse events, 4 patients (7.8%) were in the 
placebo arm and 6 (10.0 %) were in the methotrexate arm (P =.75; Supplementary Table 2). Forty patients 
discontinued the trial because of adverse events, 24 of 51 (47.1%) in the placebo arm and 16 of 60 (26.7%) in the 
methotrexate arm (P = .03), most of the withdrawals, as noted previously, were due to continuing disease 
activity. Significantly more patients treated with methotrexate experienced nausea or vomiting than those who 
received placebo (21.7% vs 3.9% in the placebo arm; P = .006); however, only 2 patients discontinued the trial 
for this reason. 
 
Discussion 
This randomized, placebo-controlled, double-blind trial evaluated the efficacy of parenteral methotrexate at a 
dosage of 25 mg/wk in patients with steroid-dependent UC. Parenteral methotrexate was not superior to placebo 
based on a composite end point consisting of remission according to all items of the Mayo score and complete 
steroid withdrawal at week 16. Actually, the observed benefit was below that expected (absolute risk difference 
of 12% rather than 25%). Methotrexate was, however, superior to placebo for inducing clinical remission 
without steroids at week 16, a definition based on the 3 clinical items of the Mayo Disease Activity Index. 
Furthermore, these data suggest that methotrexate may usefully rescue therapy in patients with treatment 
refractory UC. Indeed, 58% and 22% of the patients, respectively, were refractory or intolerant to thiopurines 
and anti-TNFs. Prior exposure to these agents did not significantly affect the chances of success or clinical 
remission. Another relevant indicator of clinical efficacy was also consistent with a benefit of methotrexate. 
Significantly more patients in the placebo arm experienced continued UC disease activity that required 
withdrawal from the study. 
The strength of the trial is that it is the first study to evaluate an adequate dosage of methotrexate administered 
parenterally in UC. Several retrospective and prospective open-label studies of methotrexate in UC have been 
published.16 Collectively, these studies suggest that 25 mg parenteral methotrexate might be an effective therapy, 
as in the case for CD.16 In contrast, low-dose oral methotrexate has been associated with low response rates.16 
The only randomized, placebo-controlled trial of methotrexate performed in UC tested oral methotrexate at a 
dosage of 12.5 mg weekly11 No difference in efficacy was demonstrated between methotrexate and placebo. In 
CD, the bioavailability of oral methotrexate plateaus at approximately 15 mg/wk, and with subcutaneous 
administration, it increases linearly at higher dosages.18,19 
Our study had some limitations. First, central reading was not used to score the study endoscopies. This process 
might have improved the interpretation of this outcome. In recent studies, up to 20%—30% of patients reported 
to have endoscopically active disease by site readers had inactive disease as judged by central readers.20 In the 
present trial, a significantly higher proportion of methotrexate-treated patients reported no rectal bleeding at 
week 16 compared with patients who received placebo. Given that the absence of rectal bleeding is highly 
correlated with endoscopic remission,21 failure to demonstrate a benefit of methotrexate treatment on endoscopic 
remission may have been due to the poor sensitivity of the site reads. Second, the efficacy of methotrexate as a 
maintenance therapy in UC was not evaluated. The MERIT-UC (Methotrexate in Induction and Maintenance of 
Steroid Free Remission in Ulcerative Colitis) study (registered as ClinicalTrials.gov ID NCT01393405) is 
currently studying the efficacy of parenteral methotrexate as maintenance therapy in UC. Finally, we did not 
require patients to have endoscopically active disease at entry, and it could be argued that inclusion of 
endoscopically inactive patients might have reduced the capacity of the trial to detect a difference in the primary 
outcome measure. However, there was no difference in outcomes (remission or endoscopic remission without 
steroids at week 16) whether patients had endoscopic activity or not at inclusion (Supplementary Table 4). 
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Figure 1. Main endpoints of the METEOR trial. (A) Primary end point: steroid-free remission at week 16. (B) 
Secondary end point: steroid-free clinical remission at week 16. (C) Secondary end point: steroid-free 
endoscopic healing at week 16. 
 
 
In this study, severe adverse events were rare and their incidence was similar in both arms. Because low-dose 
methotrexate has been used for decades in various inflammatory disorders, its safety profile is well 
characterized.16 Serious adverse events include liver toxicity, bone marrow suppression, hypersensitivity 
pneumonitis, serious infection, and teratogenicity. The risk of cancer associated with methotrexate therapy has 
been assessed in patients with rheumatoid arthritis and most studies have not found an increased risk22 In 
comparison, treatment with thio-purines increases the risk of lymphoma and nonmelanoma skin cancer.3,23-25 
Nausea and vomiting were the most common minor adverse events associated with methotrexate therapy. 
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However, only 2 patients discontinued treatment due to nausea, and most patients' symptoms were controlled or 
prevented with premedication with antiemetics. The adverse event most frequently reported that led to 
discontinuation was persistent disease activity, which occurred in a higher proportion of patients in the placebo 
group. 
The results of methotrexate can be compared with those obtained with azathioprine and anti-TNFs. Ardizzone et 
al17 randomized 72 patients with steroid-dependent UC between azathioprine and mesalamine. At 6 months, 53% 
of patients who received azathioprine were in steroid-free remission vs 21% of those who received mesalamine 
(odds ratio = 4.78; 95% CI: 1.57-14.5). Maté-Jiménez et al26 randomized 34 patients with UC to 6-
mercaptopurine, methotrexate (15 mg weekly), and mesalamine.26 Steroid-free remission was obtained in 79% of 
patients who received azathioprine, 58% of patients who received methotrexate, and 25% of patients who 
received mesalamine (P < .05 for azathioprine vs mesalamine; P = NS for methotrexate vs mesalamine and for 
methotrexate vs azathioprine). Steroid-free remission was a secondary end point of the pivotal trials of anti-
TNFs in UC. At week 30, in the ACT-1 and ACT-2 (Active Ulcerative Colitis Trials 1 and 2) trials, 21.5% of the 
patients on infliximab reached steroid-free remission vs 7.2% with placebo (P = .007).4 In the SUCCESS trial, 
24%, 22%, and 40% of the patients who were randomized to azathioprine, infliximab, or both, achieved steroid-
free remission at week 16, respectively.5 In the ULTRA-2 (Ulcerative Colitis Long-Term Remission and 
Maintenance With Adalimumab 2) trial, approximately 31% of the patients who received adalimumab were off 
steroids at week 16 vs 16% of patients allocated to placebo.27 In the PURSUIT (Program of Ulcerative Colitis 
Research Studies Utilizing an Investigational Treatment) maintenance trial of golimumab, 34.4% of UC patients 
treated with golimumab and 20.7% of patients who received placebo reached steroid-free remission at week 54 
(P = .024).28 Therefore, anti-TNFs are more efficient than placebo to obtain steroid-free remission. However, it 
is worth mentioning that steroid-dependent patients were not identified as such in all pivotal trials of anti-TNFs. 
In conclusion, our study failed to show that parenteral methotrexate is beneficial for induction of steroid-free 
remission in UC. However, methotrexate induced clinical remission without steroids at week 16 more frequently 
than placebo, and was associated with better control of disease-related symptoms. Additional studies are required 
to define the potential benefit of methotrexate as a maintenance therapy. 
 
 
Table 2. Other Secondary End Points of the METEOR (Controlled, Randomized, Double-Blind, Multicenter 
Study Comparing Methotrexate vs Placebo in Steroid-Dependent Ulcerative Colitis) Trial in the Methotrexate 
and Control Arms 









Steroid-free remission at wk 24 17 (33.3) 21 (35.0) 1.7 (-16.0 to 19.4) 1.05 (0.62 to 1.76) .85 
Steroid-free remission at wk 16 and 24 8 (15.7) 13 (21.7) 6.0 (-8.5% to 20.4) 1.38 (0,62 to 3,07) .42 
Steroid-free clinical remission at wk 24 18 (35.3) 24 (40.0) 4.7 (-13.3 to 22.8) 1.13 (0.70 to 1.84) .61 
Steroid-free clinical remission at wk 16 and 24 10 (19.6) 16 (26.7) 7.1 (-8.6 to 22.7) 1.36 (0.68 to 2.73) .38 
Steroid-free endoscopic healing at wk 24 17 (33.3) 24 (40.0) 6.7 (-11.3 to 24.6) 1.20 (0.73 to 1.97) .47 
Steroid-free endoscopic healing at wk 16 and 24 9 (17.7) 13 (21.7) 4.0 (-10.8 to 18.8) 1.23 (0.57 to 2.63) .60 
CRP <5 mg/L without steroids at wk 16 11 (21.6) 20 (33.3) 11.8 (-4.7 to 28.2) 1.55 (0.82 to 2.91) .17 
IBDQ ≥ 170 without steroids at wk 16 10 (19.6) 15 (25.0) 5.4 (-10.1 to 20.8) 1.28 (0.63 to 2.59) .50 
CRP, C-reactive protein; IBDQ, Inflammatory Bowel Disease Questionnaire. 
 
 
Table 3.Success Rates of Individual Items of the Mayo Clinical Subscore in the Methotrexate and Control Arms 
at Week 16 
Items Placebo, 
 n (%) (n = 51) 
Methotrexate, 
n (%) (n = 60) 
Absolute risk 
difference,  




Rectal bleeding score = 0 and no steroids 11 (21.6) 28 (46.7) 25.1 (8.2 to 42.0) 2.16 (1.20 to 3.90) .006 
Stool frequency score = 0 and no steroids 9 (17.7) 22 (36.7) 19.0 (3.0 to 35.1) 2.08 (1.05 to 4.10) .03 
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Table 4.Adverse Events Affecting at Least 5% of Patients Receiving Methotrexate 
Adverse events Placebo 
(n = 51) 
Methotrexate 
(n = 60) 
Any AE 37 (72.5) 45 (75) 
Serious AEs 4 (7.8) 6 (10) 
Discontinued due to AE 24 (47.1) 16 (26.7) 
Upper respiratory tract infection 3 (5.9) 8 (13.3) 
Nausea or vomiting 2 (3.9) 13 (21.7) 
Fatigue 5 (9.8) 9 (15) 
Abdominal pain 6 (11.8) 8 (13.3) 
Arthralgia 5 (9.8) 7 (11.7) 
Diarrhea 1 (2) 4 (6.7) 
Headache 3 (5.9) 4 (6.7) 
Muscular pain 1 (2) 4 (6.7) 
UC activity 24 (47.1) 13 (21.7) 
Abnormal liver function tests 1 (2) 4 (6.7) 
Injection site reaction 1 (2) 3 (5) 
Influenza viral infection 4 (7.8) 4 (6.7) 
NOTE. Values are n (%). AE, adverse event. 
 
Supplementary Material 
Note: To access the supplementary material accompanying this article, visit the online version of 
Gastroenterology at www.gastrojournal.org, and at http://dx.doi.org/10.1053/j.gastro.2015.10.050. 
Algorithm for Methotrexate Dosage Reduction in Case of Serious Toxicity 
Leukoneutropenia 
In case of leukoneutropenia during the treatment, the following therapeutic attitude will be adopted. If the 
leukocytes are <3000/mm3 and/or the neutrophils are <1500/mm3, the next methotrexate injection will not be 
performed. A new complete blood count will be performed. If the leukocytes are >3000/mm3 and/or the 
neutrophils are >1500/mm3, the methotrexate will be restarted at a dosage of 20 mg/wk. In case of persistent 
leukoneutropenia, methotrexate will be stopped. 
Abnormal Liver Tests 
In case of an unexplained rise of aspartate aminotransferase and/or  alanine  aminotransferase  >2N,  the  next 
injection will be suspended. New transaminases analysis will be carried out every week. Once their level reaches 
the baseline again, methotrexate will be restarted at a dosage of 20 mg/wk. In case of persistent increased 
transaminase levels, methotrexate will be stopped. 
Mucositis, Digestive Intolerance, and Other Abnormalities 
In case of mucositis or oral ulcerative lesions, the treatment will have to be stopped. A treatment with folinic 
acid will be administered (50—100 mg intravenously every 6 hours). 
In case of an increased serum creatinine level (>30% compared with day 0 baseline dosage), and confirmed by a 
second measurement performed with 1-week interval, the treatment will have to be discontinued. 
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Supplementary Table 1.Time During Which the Starting Dose of Prednisone or Prednisolone Was Kept 
Unchanged in the METEOR (Controlled, Randomized, Double-Blind, Multicenter Study Comparing 
Methotrexate vs Placebo in Steroid Dependent Ulcerative Colitis) Trial 
Prednisone dosage at 
inclusion, mg/d 











Supplementary Table 2.Severe Adverse Events in the Placebo and Methotrexate Arm 
Adverse events n 
Placebo 
   UC activity 2 
   Atrial fibrillation 1 
   Cancer relapse 1 
Methotrexate 
   UC activity 2 
   Pulmonary embolism 1 
   Arthralgia 1 
   Arthralgia, abdominal pain, and tremor 1 
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Supplementary Table 3. Subgroup Analyses of the Efficacy of Methotrexate and Placebo in Patients With 





n (%) (n = 51) 
Methotrexate,  
n (%) (n = 60) 
Steroid-free remission 
(methotrexate vs control), 
RR (95% CI) 
P value P value 
interaction 
Age 
   ≤42 y 4/24 (16.7) 8/31 (25.8) 1.55 (0.53-4.54) .42 .82 
   >42y 6/27 (22.2) 11/29 (37.9) 1.71 (0.73-3.97) .2  
Sex 
   Male 4/25 (16.0) 11/34 (32.4) 2.02 (0.73-5.61) .15 .56 
   Female 6/26 (23.1) 8/26 (30.8) 1.33 (0.54-3.31) .53  
Duration of disease 
   ≤4y 6/24 (25.0) 12/33 (36.4) 1.45 (0.64-3.33) .36 .86 
   >4y 4/27 (14.8) 7/27 (25.9 1.75 (0.58-5.29) .31  
Site of disease 
   Distal 4/11 (36.4) 5/17 (29.4) 0.81 (0.28-2.37) 1 .33 
   Left colon 3/12 (25.0) 6/17 (35.3) 1.41 (0.44-4.56) .69  
   Extensive 3/28 (10.7) 8/26 (30.8) 2.87 (0.85-9.68) .07  
Disease activity 
   Inactive disease 4/14 (28.6) 8/18 (44.4) 1.56 (0.59-4.13) .36 .93 
   Active disease 6/37 (16.2) 11/42 (26.2) 1.61 (0.66-3.94) .28  
IS use before enrollment 
   No 3/21 (14.3) 9/25 (36.0) 2.52 (0.78-8.12) .09 .31 
   Yes 7/30 (23.3) 10/35 (28.6) 1.22 (0.53-2.82) .63  
Prednisone-equivalent dose, mg/d 
   ≤20 3/22 (13.6) 11/29 (37.9) 2.78 (0.88-8.79) .054 .18 
   >20 7/29 (24.1) 8/31 (25.8) 1.07 (0.44-2.57) .88  
Hemoglobin 
   Normal 9/42 (21.4) 15/48 (31.3) 1.46 (0.71-2.98) .29 .5 
   Abnormal 1/9 (11.1) 4/12 (33.3) 3 (0.4-22.47) .34  
C-reactive protein serum level 
   Normal 4/33 (12.1) 9/36 (25.0) 2.06 (0.7-6.07) .17 .47 
   Abnormal 5/17 (29.4) 7/21 (33.3) 1.13 (0.44-2.94) .8  
IS, Immunosuppressives; RR, relative risk. 
 
Supplementary Table 4.Subgroup Analysis of the Efficacy of Methotrexate and Placebo in Patients With and 
Without Endoscopic Activity at Inclusion 
 Placebo,  
n (%) (n = 51) 
Methotrexate, 
n (%) (n = 60) 
Steroid-free remission 
(methotrexate vs control), 
RR (95% CI) 
P value P value 
interaction 
Endoscopic Mayo 
Inactive disease 7/27 (25.9) 14/34 (41.2) 1.59 (0.75-3.37) .21 .85 
Active disease 3/24 (12.5) 5/26 (19.2) 1.54 (0.41-5.76) .70  
   Steroid-free endoscopic 
healing (methotrexate vs 
control), RR (95% CI) 
  
Endoscopic Mayo 
Inactive disease 8/27 (29.6) 16/34 (47.1) 1.59 (0.80-2.14) .17 .34 
Active disease 5/24 (20.8) 5/26 (19.2) 0.92 (0.30-2.80) 1  
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